Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Chlodantane and PE-22-28 — mechanism, dosing, side effects, legal status, and pricing.
Chlodantane (ADK-910) is a non-peptide aryl-substituted 2-aminoadamantane amide, structurally related to bromantane and classified in Soviet pharmacological literature as an actoprotector/adaptogen. It has never been approved for human use in any jurisdiction and remains entirely unevaluated in clinical trials. All available data derive from animal and cell-culture experiments conducted in the former Soviet Union.
PE-22-28 is a 7-amino-acid synthetic analog of spadin, a peptide fragment (residues 22-28) of the 44-aa propeptide (PE) released during post-translational maturation of sortilin (the neurotensin receptor-3). It is studied in preclinical models as a fast-acting antidepressant that works by selectively blocking the TREK-1 two-pore potassium channel. There is no established use for hair growth — that is a separate compound and the two should not be confused.
Chlodantane
PE-22-28
Category
Legal Status
Mechanism
Dose Range
Route
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Chlodantane
No pricing data yet.
Check Chlodantane prices →PE-22-28
COA corpus from Disclosed Labs — independently tested batches only.
Chlodantane
1
COAs
99.9%
Avg purity
1
Labs
PE-22-28
13
COAs
99.6%
Avg purity
7
Labs
No human data exist; a 2012 review explicitly states that all pharmacological data derive from animal or cell-culture experiments, with no clinical research conducted. In unspecified animal models, chlodantane enhanced resistance to physical and toxic-chemical stressors, produced immunostimulating effects in stress-induced immunodeficiency, and protected against hypoxia, high and low ambient temperature, and toxic chemical challenge. Effects were reported to appear after a single administration, and immunostimulant activity was described as more pronounced than that of bromantane.
Mazella, Borsotto and colleagues at Nice, France identified spadin (Mazella et al., PLoS Biology 2010, PMID 20405001) and subsequently developed shortened PE 22-28 analogs with ~300× improved TREK-1 affinity and longer in vivo half-life (Djillani et al., Front Pharmacol 2017, PMID 28955242). In mouse antidepressant assays (forced swim, tail suspension, novelty-suppressed feeding), acute or 4-day IP dosing at ~3–4 μg/kg produced effects comparable to chronic SSRI treatment; oral gavage at 1 mg/kg was also active. The G/A-PE 22-28 modification extended duration of action to ~21–23 hours. Chronic dosing did not produce cardiac or seizure signals in rodents. No human clinical trials have been conducted. A detailed review of TREK-1 blockers for depression is available in Djillani et al., Pharmacol Ther 2019 (PMID 30291907).
Chlodantane (Performance) and PE-22-28 (Cognitive) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Frequency
Dosing Notes
Half-life
Side Effects
Contraindications
Lab Testing
Disclosed Labs